Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian (Europe)
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian (Europe)
The Guardian view on Trump and China : stepping back from the brink, but not solving problems | Editorial
30/10/2025
The Guardian view on deprived neighbourhoods : incomes as well as places need a boost | Editorial
30/10/2025
US will limit number of refugees to 7,500 and give priority to white South Africans
30/10/2025
UN leaders condemn ‘horrifying’ mass killings in Sudan
30/10/2025
OpenAI thought to be preparing for $1tn stock market float
30/10/2025
Four feet higher and rising : Barcelona’s Sagrada Familia becomes world’s tallest church
30/10/2025